Work Here?
Overview
Prima Mente combines AI with neuroscience to study the human brain. It generates its own biological datasets and builds advanced AI models to translate discoveries into clinical and research applications, focusing on understanding brain biology and developing treatments for neurological conditions. The company uses a multidisciplinary team and a flat, collaborative culture to tackle complex problems with multi-omics and multi-modal models, sharing findings through influential publications. Its goal is to protect against neurological diseases and improve cognitive health at scale, aligning with global health priorities (SDG 3). Compared with others, Prima Mente differentiates itself through in-house data generation, a strong emphasis on neurobiology and AI integration, and a collaborative, fast-paced environment aimed at delivering real patient impact.
About Prima Mente
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2022
Simplify's Take
What believers are saying
- Pleiades achieves 0.89 accuracy detecting Alzheimer's from blood.
- $1M Alzheimer's AI Prize win boosts credibility and partnerships.
- 1,000-patient study launches next month with NHS SANDBOX pilot.
What critics are saying
- Biomni-AD's superior AI erodes PARTHENON's lead within 6-12 months.
- NVIDIA's GPU shift obsoletes Pleiades, halting pilots in 12-24 months.
- 48-person team fails scaling proteomics, delaying 2026 generalizability.
What makes Prima Mente unique
- Prima Mente integrates AI with neuroscience via Pleiades epigenome model.
- PARTHENON virtual lab compresses weeks of experiments into minutes.
- Multi-omics wet lab generates high-throughput data for Alzheimer's biomarkers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Growth Opportunities
Company News
The Alzheimer's Disease Data Initiative has doubled its prize competition, awarding $1 million each to two winners — Biomni-AD and Prima Mente — in the Alzheimer's Insights AI Prize. The competition, backed by Bill Gates, sought agentic AI solutions to accelerate Alzheimer's and dementia research. Launched in August 2025, the prize drew over 180 submissions. Biomni-AD developed an AI "co-scientist" that performs time-consuming research tasks in minutes with high accuracy. Prima Mente created PARTHENON, a virtual laboratory platform that compresses weeks of experimental work into minutes. Both solutions will be made freely available to researchers worldwide through the AD Data Initiative's platform. With Alzheimer's projected to affect 152 million people by 2050, the competition reflects urgent demand for innovative approaches to tackle fragmented research data.
There are no jobs for Prima Mente right now.
Find jobs on Simplify and start your career today
About Prima Mente
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2022
There are no jobs for Prima Mente right now.
Find jobs on Simplify and start your career today